Immunotherapy / PD-1 inhibitorFDA-approvedAdjuvant
Provenge
Generic name: sipuleucel-T
How it works
Trains the immune system to recognize and attack prostate cancer cells.
Cancer types
Prostate Cancer— All patients
Efficacy
In clinical trials, around 22% of men with metastatic prostate cancer achieved an objective response, with median overall survival of approximately 4 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Evaluating Sipuleucel-T in Combination with Hormonal Agents for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Exploring Cancer Treatment with PET Scans in Prostate Cancer Patients | Prostate Cancer | phase-2 | — | Source → |
| Combining Sipuleucel-T with Other Treatments for Prostate Cancer | Prostate Cancer | review | — | Source → |
| Hidden Heart Risks in Prostate Cancer Treatment | Prostate Cancer | observational | — | Source → |
| Combining Sipuleucel-T and Androgen Receptor-Targeting Agents May Improve Survival in Prostate Cancer | Prostate Cancer | observational | Men who received sipuleucel-T and ARTAs had a 28.3% lower risk of death than those who received ARTA monotherapy. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.